GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Cash Flow from Financing

Accelerated Pharma (Accelerated Pharma) Cash Flow from Financing : $1.55 Mil (TTM As of Mar. 2017)


View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2017, Accelerated Pharma paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.29 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It spent $0.05 Mil on other financial activities. In all, Accelerated Pharma earned $0.24 Mil on financial activities for the three months ended in Mar. 2017.


Accelerated Pharma Cash Flow from Financing Historical Data

The historical data trend for Accelerated Pharma's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Cash Flow from Financing Chart

Accelerated Pharma Annual Data
Trend Dec14 Dec15 Dec16
Cash Flow from Financing
- 2.15 1.31

Accelerated Pharma Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Cash Flow from Financing Get a 7-Day Free Trial - 0.44 0.72 0.15 0.24

Accelerated Pharma Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Accelerated Pharma's Cash from Financing for the fiscal year that ended in Dec. 2016 is calculated as:

Accelerated Pharma's Cash from Financing for the quarter that ended in Mar. 2017 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accelerated Pharma  (NAS:ACCP) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Accelerated Pharma's issuance of stock for the three months ended in Mar. 2017 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Accelerated Pharma's repurchase of stock for the three months ended in Mar. 2017 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Accelerated Pharma's net issuance of debt for the three months ended in Mar. 2017 was $0.29 Mil. Accelerated Pharma received $0.29 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Accelerated Pharma's net issuance of preferred for the three months ended in Mar. 2017 was $0.00 Mil. Accelerated Pharma paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Accelerated Pharma's cash flow for dividends for the three months ended in Mar. 2017 was $0.00 Mil. Accelerated Pharma received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Accelerated Pharma's other financing for the three months ended in Mar. 2017 was $-0.05 Mil. Accelerated Pharma spent $0.05 Mil on other financial activities.


Accelerated Pharma Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerated Pharma (Accelerated Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Website
Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines